AROG Pharmaceuticals, LLC is attending AACR 2012, meeting in Chicago
Jan 11, 2012 AROG Pharmaceuticals, LLC (AROG) will be presenting three posters describing differentiated mechanism of action for crenolanib.
About Crenolanib
Cernolanib is a next generation inhibitor of receptor tyrosine kinases with the following attributes:
- Unique chemo-type with benzimidazole backbone
- Preferentially inhibits phosphorylated receptors
- Activity against wild type & mutant receptors
- Specificity for PDGFRα, PDGFRβ and FLT3
- No activity against VEGFR or FGFR
There are three ongoing clinical trials of crenolanib in the US:
- A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas (NCT01229644)
- A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of GIST (NCT01243346)
- Phase I Study of Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor, Crenolanib in Newly Diagnosed and Recurrent High-grade Pediatric Glioma Including Diffuse Intrinsic Pontine Glioma (NCT01393912)
About AROG Pharmaceuticals, LLC
AROG is a private, oncology-focused biopharmaceutical company based in Dallas, TX. AROGs mission is to develop novel anticancer drugs for the treatment of rare cancers with significant unmet medical need. To learn more about AROG, please visit www.arogpharma.com